Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

IDEXX Laboratories stock

IDXX
US45168D1046
888210

Price

452.77
Today +/-
-0.09
Today %
-0.02 %

IDEXX Laboratories stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the IDEXX Laboratories stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the IDEXX Laboratories stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the IDEXX Laboratories stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze IDEXX Laboratories's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

IDEXX Laboratories Stock Price History

DateIDEXX Laboratories Price
2/20/2025452.77 undefined
2/19/2025452.86 undefined
2/18/2025450.99 undefined
2/17/2025449.06 undefined
2/13/2025444.53 undefined
2/12/2025459.76 undefined
2/11/2025457.35 undefined
2/10/2025463.74 undefined
2/9/2025464.91 undefined
2/6/2025459.78 undefined
2/5/2025460.56 undefined
2/4/2025468.55 undefined
2/3/2025465.03 undefined
2/2/2025469.04 undefined
1/30/2025422.05 undefined
1/29/2025423.99 undefined
1/28/2025418.75 undefined
1/27/2025417.86 undefined
1/26/2025427.52 undefined

IDEXX Laboratories Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into IDEXX Laboratories, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by IDEXX Laboratories from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects IDEXX Laboratories’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of IDEXX Laboratories. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into IDEXX Laboratories’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing IDEXX Laboratories’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on IDEXX Laboratories’s growth potential.

IDEXX Laboratories Revenue, EBIT and net profit per share

DateIDEXX Laboratories RevenueIDEXX Laboratories EBITIDEXX Laboratories Net Income
2028e5.5 B undefined1.62 B undefined1.38 B undefined
2027e4.94 B undefined1.6 B undefined1.28 B undefined
2026e4.54 B undefined1.44 B undefined1.13 B undefined
2025e4.2 B undefined1.3 B undefined1 B undefined
20243.9 B undefined1.13 B undefined887.87 M undefined
20233.66 B undefined1.1 B undefined845.04 M undefined
20223.37 B undefined902.2 M undefined679.1 M undefined
20213.22 B undefined934.1 M undefined744.8 M undefined
20202.71 B undefined695.1 M undefined581.8 M undefined
20192.41 B undefined553.9 M undefined427.7 M undefined
20182.21 B undefined497 M undefined377 M undefined
20171.97 B undefined414.1 M undefined263.1 M undefined
20161.78 B undefined351.5 M undefined222 M undefined
20151.6 B undefined308.1 M undefined192.1 M undefined
20141.49 B undefined260.3 M undefined181.9 M undefined
20131.38 B undefined266.8 M undefined187.8 M undefined
20121.29 B undefined262.6 M undefined178.3 M undefined
20111.22 B undefined236.2 M undefined161.8 M undefined
20101.1 B undefined203.9 M undefined141.3 M undefined
20091.03 B undefined176 M undefined122.2 M undefined
20081.02 B undefined172.5 M undefined116.2 M undefined
2007922.6 M undefined136.2 M undefined94 M undefined
2006739.1 M undefined127.9 M undefined93.7 M undefined
2005638.1 M undefined115.3 M undefined78.3 M undefined

IDEXX Laboratories Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)NET INCOME (B)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
1989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e2028e
0.020.020.030.060.090.130.190.270.260.320.360.370.390.410.480.550.640.740.921.021.031.11.221.291.381.491.61.781.972.212.412.713.223.373.663.94.24.544.945.5
-33.3325.00103.3352.4635.4849.2142.55-1.4921.5911.532.515.186.7415.5315.3416.2115.8324.7611.060.686.9810.436.166.507.847.8110.8710.9312.398.7212.4718.814.738.706.487.788.058.9211.29
50.0058.3356.6757.3859.1457.9456.9155.9745.0848.9148.0448.2347.4146.6048.3250.8250.4751.2950.2251.6651.0252.4053.0454.0654.9054.9555.5954.9355.7156.0856.7358.0658.7659.5259.8161.0256.6252.4048.1143.23
0.010.010.020.040.060.070.110.150.120.160.170.180.180.190.230.280.320.380.460.530.530.580.650.70.760.820.890.981.11.241.371.571.8922.192.380000
0-000.010.010.010.020.03-0.02-0.020.030.040.040.050.060.080.080.090.090.120.120.140.160.180.190.180.190.220.260.380.430.580.740.680.850.8911.131.281.38
--500.00-175.0066.6780.0044.4461.5452.38-165.63-28.57-313.3312.502.7821.6226.6736.84-19.231.0823.405.1715.5714.1810.565.06-3.216.0815.6318.4743.3513.2636.0728.06-8.7424.454.9712.8513.2913.237.17
59.555.591.5123.3132.5134.1141.4158.1151.9154.1159144.3138.6140.2143.7143.2136.2131.8128.9124.5121.4119.1116.4112.3108101.593.690.989.688.587.586.786.684.683.9883.250000
----------------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The IDEXX Laboratories Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the IDEXX Laboratories is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (B)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (B)UNREAL. GAINS/LOSSES (k)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (B)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
19901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                                                     
7.914.831.939.450.4183.7173.6142.5138.4105.475.272.6147.2220.7137.3132.796.760.478.9106.7156.9183.9224279.1322.5342.6391.9471.9123.890.3383.9144.5112.5453.93288.27
4.45.112.621.425.856.866.647.347.958.457.350.845.75465.671.781.4108.4111.5115.1120.1141.3138.3158152.4188.3204.5234.6258.5287355.3406.1442.5512.56473.58
00000000000000000000000028.911.827.735.514.120.519.419.548.416.970
3.45.113.114.620.828.248.460.255.447.565.986.275.175.376.469.49698.8115.9110.4127.9133.1140.9133.4160.3188.8158164.3173.3195209.9269367.8380.28381.88
0.41.41.61.41.62.81324.221.621.217.4262020.622.325.528.238.149.644.155.76666.382.295.290.163.565.784.486.894.2116.6130.2131.51256.18
0.020.030.060.080.10.270.30.270.260.230.220.240.290.370.30.30.30.310.360.380.460.520.570.650.760.820.850.970.650.681.060.961.11.51.4
2.211121213.425.536.442.441.539.645.749.249.545.262.665.799.6141.9189.6199.9201.7216.8245.2281.2303.6333357.4379.1437.3614.5646.3692.8768.1817.68713.12
0000013.67.311.117.325.502115.635.119.700000000010.812.2119.910.913.712.118.655.556.190
000000000000000000000000000031.381.298124149.7167.960
00.6000213.42224.825.425.34.53.86.831.630.643.478.368.363.955.869.262.858.865.155.946.243.841.858.552.59997.784.50
0010.48.98.2-2.610.4182923.936.650.752.35592.988.1104.8158.1138.8148.7149.1172.6175180.5184.5178.9178.2199.9214.5239.7243.3359.3361.8365.960
00000000.010.010.010.010.010.010.010.010.010.010.020.010.020.030.050.050.060.060.070.090.110.150.150.180.190.210.271.18
00.010.020.020.020.040.070.10.120.130.120.140.130.150.210.190.260.40.410.430.440.510.530.580.620.650.690.740.881.151.231.481.651.761.89
0.020.040.080.10.120.310.370.380.390.360.340.370.420.520.510.490.560.70.770.810.91.031.11.231.381.471.531.711.541.832.292.442.753.263.29
                                                                     
3.30.51.51.63.23.73.83.83.9444.14.24.65.25.96.511.712.213.914.214.614.615.215.315.715.816.4151515.116.415.916.280
0.020.040.070.070.070.230.250.260.280.280.30.310.330.380.410.440.480.510.550.580.640.70.760.830.890.941.011.071.141.211.291.381.461.570
-0.01-000.010.020.050.070.050.030.060.10.140.180.240.320.40.490.590.70.820.971.131.311.491.680.320.540.81.171.62.182.923.64.440
0-0-0-0-0-0-0-0-0-0-0.01-0.01-000.0100.010.020.010.010.010.020.020.01-0.01-0.04-0.04-0.04-0.04-0.05-0.05-0.05-0.08-0.071.6
0000000000000000000000-2001000-20000-200100-300-100-200-1640
0.010.030.070.080.10.280.320.30.310.350.40.450.520.630.750.840.991.141.271.431.631.862.092.352.571.231.531.862.282.783.434.2655.961.6
1.23.14.47.29.210.818.712.526.821.813.710.99.419.214.719.824.432.52819.122.736.635.329.944.752.660.16769.572.274.6116.1110.2110.64114.21
2.13.35.56.710.510.717.23629.127.829.929.743.449.155.556.170.58991.395106.3123.7132.9127.5164.5184.8211.1224233.5288.9373416.3385.1392.16502.12
1.20.20.20.42.310.212.221.713.420.421.922.416.531.628.430.129.228.924.622.626.332.725.142.962.746.352.458.668.575.585.282.686.5123.7533.8
000001.73003.58.58.410.51.30.6072.2150.6118.8129243212277549573611655398.9288.8073.5579250250
0.10000002.65.200000000.70.70.80.80.90.91.1100000050757575167.79
00.010.010.010.020.030.050.070.070.070.070.070.070.10.10.110.120.220.30.260.290.440.410.480.820.860.9310.770.730.580.761.240.951.07
00000001.44.2000000.506.45.75.14.33.42.51.4150.4350500499.4499.5499.6599.5858.5775.2694.4622.88449.79
0000000000000.20.28.567.214.711.918.318.723.32333.941.749.439.325.429.33311.78.98.27.240
00000000000067.27.38.811.42014.915.115.728.636.649.654152.8165.6237.8247.3296.8208.8199.5199.7193.73180.43
0000000000000.010.010.020.010.030.040.030.040.040.050.060.230.450.70.70.760.780.931.080.980.90.820.63
00.010.010.010.020.030.050.070.080.070.070.070.080.110.120.120.150.260.330.290.320.490.470.711.271.561.641.771.551.651.661.752.141.781.7
0.020.040.080.10.120.310.370.380.390.420.470.520.60.740.860.961.141.41.61.721.962.352.563.063.842.793.163.623.834.435.096.017.147.733.29
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of IDEXX Laboratories provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand IDEXX Laboratories's financial health and stability.

Assets

IDEXX Laboratories's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that IDEXX Laboratories must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of IDEXX Laboratories after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into IDEXX Laboratories's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
19891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
1-4359132132-21-15323637455778789394116122141161178187182192222263377427582744679845
001334510141517192220181824294148494648525458697883838896104111114
00000000-1402303-14-4-6-95306-220520-716-38-3-35-48
-100-8-6-3-17-272070-31-133321-1310-10-1-32-12-60-9-3-9-6478-91-105-31-137-273-72
020000001437000020772101623111618212239304955817084110127
000000000000000000452233512273137342932303941
000039121281712131916425343636494548446867605474816988110161239192
0030714915134652284610311795116109135143175178217222246235221338373400459648755543906
-1-1-10-12-2-5-19-31-35-48-12-27-17-15-19-83-31-69-155-94-51-39-50-58-78-60-82-64-76-122-155-107-119-158-133
-52-16-20-8-11-42-38-32-48-3924-26-46-87-3612-40-121-91-53-43-94-58-86-80-308-90-138138-205-109-293-195-125
-44-5-8-6-6-22-720-2651-8-31-68464428333-2-3-430-7-19-225-26-62261-50-1-173-368
00000000000000000000000000000000000
0000001-1-1-2-6-30-700-207079-339113-312134702743844-256-10-8923430-404
70152922155435-57-601-17-4-109-104-84-97-116-66-114-226-108-329-588-379-265-243-331-265-131-700-784-24
70152922157213-64-630-25-5-110-107-76-18-30-95-86-97-125-102-103-101-222-208-597-286-248-697-370-441
000000000000000009965181614131445-8-10-10-27-20-17-13
00000000000000000000000000000000000
122806124-21-202-50-12203327-4920-5-118275026405543-1932532-63-33293-239-31341
-1-1.9-7.3-12.15.29.5-10-16.2-22.1-240.20.72987.89812.484.840.2-19.948.6123.8139.5167.2163.9167.4175.1138.9274.1296.6277.2304540.2636384.2772.88
00000000000000000000000000000000000

IDEXX Laboratories stock margins

The IDEXX Laboratories margin analysis displays the gross margin, EBIT margin, as well as the profit margin of IDEXX Laboratories. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for IDEXX Laboratories.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the IDEXX Laboratories's sales revenue. A higher gross margin percentage indicates that the IDEXX Laboratories retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the IDEXX Laboratories's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the IDEXX Laboratories's total revenue generated. When comparing the revenue margin year over year, investors can gauge the IDEXX Laboratories's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the IDEXX Laboratories. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the IDEXX Laboratories's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

IDEXX Laboratories Margin History

IDEXX Laboratories Gross marginIDEXX Laboratories Profit marginIDEXX Laboratories EBIT marginIDEXX Laboratories Profit margin
2028e61.04 %29.45 %25.03 %
2027e61.04 %32.31 %25.98 %
2026e61.04 %31.73 %25 %
2025e61.04 %30.93 %23.84 %
202461.04 %28.95 %22.78 %
202359.82 %30 %23.08 %
202259.52 %26.79 %20.17 %
202158.76 %29.05 %23.16 %
202058.04 %25.68 %21.49 %
201956.73 %23.01 %17.77 %
201856.1 %22.46 %17.03 %
201755.73 %21.03 %13.36 %
201654.94 %19.8 %12.5 %
201555.58 %19.23 %11.99 %
201454.93 %17.52 %12.24 %
201354.91 %19.37 %13.64 %
201254.06 %20.3 %13.79 %
201153.05 %19.38 %13.28 %
201052.44 %18.48 %12.81 %
200951.02 %17.06 %11.85 %
200851.74 %16.85 %11.35 %
200750.24 %14.76 %10.19 %
200651.35 %17.3 %12.68 %
200550.6 %18.07 %12.27 %

IDEXX Laboratories Stock Sales Revenue, EBIT, Earnings per Share

The IDEXX Laboratories earnings per share therefore indicates how much revenue IDEXX Laboratories has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue IDEXX Laboratories earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates IDEXX Laboratories's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of IDEXX Laboratories’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating IDEXX Laboratories's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

IDEXX Laboratories Revenue, EBIT and net profit per share

DateIDEXX Laboratories Sales per ShareIDEXX Laboratories EBIT per shareIDEXX Laboratories Earnings per Share
2028e67.18 undefined0 undefined16.82 undefined
2027e60.37 undefined0 undefined15.69 undefined
2026e55.42 undefined0 undefined13.86 undefined
2025e51.29 undefined0 undefined12.23 undefined
202446.82 undefined13.55 undefined10.67 undefined
202343.59 undefined13.08 undefined10.06 undefined
202239.8 undefined10.66 undefined8.03 undefined
202137.13 undefined10.79 undefined8.6 undefined
202031.22 undefined8.02 undefined6.71 undefined
201927.51 undefined6.33 undefined4.89 undefined
201825.01 undefined5.62 undefined4.26 undefined
201721.98 undefined4.62 undefined2.94 undefined
201619.53 undefined3.87 undefined2.44 undefined
201517.11 undefined3.29 undefined2.05 undefined
201414.64 undefined2.56 undefined1.79 undefined
201312.75 undefined2.47 undefined1.74 undefined
201211.52 undefined2.34 undefined1.59 undefined
201110.47 undefined2.03 undefined1.39 undefined
20109.26 undefined1.71 undefined1.19 undefined
20098.5 undefined1.45 undefined1.01 undefined
20088.22 undefined1.39 undefined0.93 undefined
20077.16 undefined1.06 undefined0.73 undefined
20065.61 undefined0.97 undefined0.71 undefined
20054.69 undefined0.85 undefined0.57 undefined

IDEXX Laboratories business model

The history of IDEXX Laboratories Inc began in 1983 when a research team from the University of Maine developed technology for the automatic analysis of animal blood. The first products were soon sold and the company grew rapidly. Today, IDEXX is a leading global provider of veterinary diagnostic and IT solutions, recognized by customers in over 175 countries. IDEXX's business model is based on innovation and a comprehensive understanding of the needs of veterinarians and their patients. The company offers a wide range of products and solutions that make the diagnosis and treatment of animal diseases easier and more reliable. These include tests and devices for blood analysis, urine and stool diagnostics, as well as imaging, infection control, and cancer diagnostics. The company has several divisions that focus on different aspects of veterinary diagnostics. IDEXX Diagnostics is the largest business segment, offering veterinary lab services, diagnostic tests, and software solutions. IDEXX Water is a company specializing in the analysis of water samples and monitoring of environmental conditions. IDEXX Livestock, the newest division of IDEXX, provides veterinary solutions for agricultural and livestock operations. Key products of IDEXX include tests for parasites, infections, diabetes, and kidney function. The company has also developed some innovative products, such as SNAP tests, which provide fast and accurate results and can perform tests for various pathogens simultaneously. IDEXX is also a company committed to sustainability. The IDEXX Foundation was established in 2013 and has since donated over $32 million to local and global projects that aim to protect animals and the environment. Overall, IDEXX Laboratories Inc is a company specialized in veterinary diagnostic and IT solutions to support veterinarians in treating animals. The wide range of solutions and products, as well as the commitment to sustainability, make the company an important player in the market for veterinary diagnostics. IDEXX Laboratories is one of the most popular companies on Eulerpool.com.

IDEXX Laboratories SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

IDEXX Laboratories Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

IDEXX Laboratories Revenue by Segment

Segmente202320222021202020192018
Product revenue2.09 B USD1.93 B USD1.88 B USD1.59 B USD1.42 B USD1.32 B USD
Service revenue1.57 B USD1.44 B USD1.34 B USD1.12 B USD983.76 M USD890.56 M USD

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

IDEXX Laboratories Revenue by Segment

Segmente202320222021202020192018
CAG Diagnostics recurring revenue:2.94 B USD-----
Veterinary software, services and diagnostic imaging systems:279.33 M USD-----
CAG Diagnostics capital - instruments137.6 M USD-----

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

IDEXX Laboratories Revenue by Segment

Segmente202320222021202020192018
Reference laboratory diagnostic and consulting services1.28 B USD1.18 B USD1.12 B USD---
IDEXX VetLab consumables--1.01 B USD---
Rapid assay products344.49 M USD313.67 M USD296.85 M USD---

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

IDEXX Laboratories Revenue by Segment

Segmente202320222021202020192018
CAG Diagnostics recurring revenue:-2.66 B USD2.53 B USD---
Veterinary software, services and diagnostic imaging systems-251.19 M USD206.26 M USD---
CAG Diagnostics capital - instruments-147.33 M USD149.14 M USD---

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

IDEXX Laboratories Revenue by Segment

Segmente202320222021202020192018
CAG Diagnostics recurring revenue:---2.11 B USD--
Veterinary software, services and diagnostic imaging systems---162.98 M USD--
CAG Diagnostics capital - instruments---108.95 M USD--

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

IDEXX Laboratories Revenue by Segment

Segmente202320222021202020192018
CAG Diagnostics recurring revenue----1.83 B USD1.65 B USD
Reference laboratory diagnostic and consulting services-----746.79 M USD
IDEXX VetLab consumables-----617.24 M USD
Veterinary software, services and diagnostic imaging systems----158.17 M USD146.63 M USD
CAG Diagnostics capital - instruments----132.69 M USD134.26 M USD
Rapid assay products-----217.54 M USD
CAG Diagnostics services and accessories-----72.96 M USD

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

IDEXX Laboratories Revenue by Segment

Segmente202320222021202020192018
CAG segment revenue3.35 B USD3.06 B USD2.89 B USD2.39 B USD2.12 B USD-
CAG-----1.94 B USD
LPD segment revenue121.66 M USD122.61 M USD135.89 M USD145.85 M USD132.64 M USD-
Water segment revenue168.15 M USD155.72 M USD146.51 M USD128.63 M USD--
Other segment revenue18.79 M USD30.2 M USD43.01 M USD46.42 M USD--
LPD-----130.58 M USD

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

IDEXX Laboratories Revenue by Segment

Segmente202320222021202020192018
Water segment revenue----132.85 M USD125.2 M USD
Other segment revenue----22.24 M USD22.04 M USD

IDEXX Laboratories Revenue by Region

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

IDEXX Laboratories Revenue by Segment

DateAmericasAsia Pacific RegionAustraliaCanadaChinaEurope, the Middle East and AfricaFranceGermanyItalyJapanLatin AmericaNetherlandsOther CountriesSpainSwitzerlandUnited KingdomUnited States
20232.63 B USD319.31 M USD-150.11 M USD-716.18 M USD--------34.83 M USD--
20222.4 B USD319.55 M USD-142.74 M USD-647.03 M USD--------30.65 M USD--
20212.2 B USD331.38 M USD---681.95 M USD--------31.98 M USD--
20201.85 B USD293.41 M USD---562.77 M USD--------24.85 M USD--
20191.65 B USD256.89 M USD---498.44 M USD-----------
20181.5 B USD238.09 M USD63.39 M USD94.21 M USD57.62 M USD472.07 M USD60.32 M USD100.46 M USD36.96 M USD60.21 M USD50.97 M USD18.09 M USD56.87 M USD33.69 M USD19.88 M USD87.81 M USD1.36 B USD
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

IDEXX Laboratories Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

IDEXX Laboratories historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

IDEXX Laboratories shares outstanding

The number of shares was IDEXX Laboratories in 2024 — This indicates how many shares 83.246 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue IDEXX Laboratories earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates IDEXX Laboratories's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of IDEXX Laboratories’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating IDEXX Laboratories's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

IDEXX Laboratories stock splits

In IDEXX Laboratories's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for IDEXX Laboratories.

IDEXX Laboratories latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/20242.45 2.62  (6.89 %)2024 Q4
9/30/20242.73 2.8  (2.49 %)2024 Q3
6/30/20242.94 3.02  (2.84 %)2024 Q2
3/31/20242.73 2.81  (3.1 %)2024 Q1
12/31/20232.16 2.32  (7.31 %)2023 Q4
9/30/20232.42 2.53  (4.66 %)2023 Q3
6/30/20232.52 2.67  (6.07 %)2023 Q2
3/31/20232.47 2.55  (3.31 %)2023 Q1
12/31/20221.98 2.05  (3.42 %)2022 Q4
9/30/20222.08 2.15  (3.32 %)2022 Q3
1
2
3
4
5
...
11

Eulerpool ESG Scorecard© for the IDEXX Laboratories stock

Eulerpool World ESG Rating (EESG©)

84/ 100

🌱 Environment

99

👫 Social

99

🏛️ Governance

55

Environment

Scope 1 - Direct Emissions
16,135
Scope 2 - Indirect emissions from purchased energy
18,014
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
34,149
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees58
Percentage of women in management
Percentage of Asian employees6.5
Share of Asian management
Percentage of Hispanic/Latino employees6.1
Hispano/Latino Management share
Percentage of Black employees8.7
Black Management Share
Percentage of white employees76.6
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

IDEXX Laboratories shareholders

%
Name
Stocks
Change
Date
11.81475 % The Vanguard Group, Inc.9,673,915-29,32212/31/2024
6.50124 % BlackRock Institutional Trust Company, N.A.5,323,219-239,97012/31/2024
4.44255 % State Street Global Advisors (US)3,637,56024,20012/31/2024
3.25214 % Fundsmith LLP2,662,855-1,30712/31/2024
2.80566 % Geode Capital Management, L.L.C.2,297,27137,73412/31/2024
2.44934 % Baron Capital Management, Inc.2,005,52282,26412/31/2024
2.04051 % Invesco Capital Management (QQQ Trust)1,670,76710,3301/31/2025
1.51346 % AllianceBernstein L.P.1,239,220-1,578,48912/31/2024
1.37777 % BlackRock Asset Management Ireland Limited1,128,11936,40412/31/2024
1.34955 % William Blair & Company, L.L.C. (Research)1,105,014-60,55512/31/2024
1
2
3
4
5
...
10

IDEXX Laboratories Executives and Management Board

Mr. Jonathan Mazelsky

(62)
IDEXX Laboratories President, Chief Executive Officer, Director (since 2012)
Compensation 9.79 M

Mr. Brian Mckeon

(60)
IDEXX Laboratories Chief Financial Officer, Executive Vice President, Treasurer (since 2003)
Compensation 3.51 M

Mr. Michael Lane

(55)
IDEXX Laboratories Executive Vice President and General Manager, Global Reference Laboratories and Information Technology
Compensation 2.54 M

Mr. James Polewaczyk

(60)
IDEXX Laboratories Executive Vice President, Chief Commercial Officer
Compensation 2.54 M

Ms. Tina Hunt

(55)
IDEXX Laboratories Executive Vice President - Strategy, Sector Development and Global Operations
Compensation 2.54 M
1
2
3
4

IDEXX Laboratories Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Applied BioCode Corporation Stock
Applied BioCode Corporation
SupplierCustomer0,840,64-0,27-0,70-0,75
Ortho Cli Dgnst Rg Stock
Ortho Cli Dgnst Rg
SupplierCustomer0,450,55-0,010,29
Zhejiang Gongdong Medical Technology A Stock
Zhejiang Gongdong Medical Technology A
SupplierCustomer0,400,10-0,550,790,89
Thermo Fisher Scientific Inc. Stock
Thermo Fisher Scientific Inc.
SupplierCustomer0,170,050,480,880,740,94
Datadog, Inc. Stock
Datadog, Inc.
SupplierCustomer-0,09-0,130,340,860,600,87
Euro Tech Holdings Company Limited Stock
Euro Tech Holdings Company Limited
SupplierCustomer-0,240,360,090,620,790,93
Luminex Stock
Luminex
SupplierCustomer-0,49-0,440,050,890,70
1

Most common questions regarding IDEXX Laboratories

What values and corporate philosophy does IDEXX Laboratories represent?

IDEXX Laboratories Inc represents strong values and a clear corporate philosophy. The company's values are centered around innovation, integrity, and collaboration. IDEXX is committed to continuously developing innovative diagnostic solutions to improve the health and well-being of animals worldwide. They uphold the highest standards of integrity in their business practices, ensuring transparency and trust with their customers and partners. Additionally, IDEXX promotes a culture of collaboration, fostering a diverse and inclusive environment that encourages teamwork and supports the growth and success of its employees. Through these values and corporate philosophy, IDEXX Laboratories Inc exemplifies its dedication to advancing animal healthcare globally.

In which countries and regions is IDEXX Laboratories primarily present?

IDEXX Laboratories Inc is primarily present in various countries and regions worldwide. As a leading veterinary diagnostics and software provider, IDEXX operates in over 175 countries. Its operations span across North America, including the United States and Canada, as well as Europe, Asia-Pacific, Latin America, and the Middle East. With a strong global presence, IDEXX consistently delivers innovative solutions and services to veterinary practices, animal healthcare professionals, and laboratories around the globe.

What significant milestones has the company IDEXX Laboratories achieved?

IDEXX Laboratories Inc, a renowned leader in veterinary diagnostics and software, has achieved numerous significant milestones over the years. The company pioneered the first veterinary reference laboratory, revolutionizing the field of animal health diagnostics. IDEXX also developed innovative technologies such as the SNAP test, providing immediate results for veterinarians. Furthermore, the company introduced groundbreaking products like the IDEXX ProCyte Dx Hematology Analyzer, enhancing the accuracy and efficiency of pet healthcare. With a commitment to continuous innovation, IDEXX Laboratories Inc has consistently redefined the standards in veterinary medicine, offering exceptional diagnostic solutions for veterinarians globally.

What is the history and background of the company IDEXX Laboratories?

IDEXX Laboratories Inc. is a leading global company in veterinary diagnostics and software solutions. Founded in 1983, IDEXX has built a strong reputation for offering innovative products and services to support the animal healthcare industry. The company's mission is to improve the health and well-being of pets, livestock, and wildlife. IDEXX provides a wide range of diagnostic tests, instruments, and digital imaging systems that help veterinarians accurately diagnose diseases and ensure the best possible care for animals. With its headquarters in Maine, USA, IDEXX has an extensive network of customers worldwide. As a pioneer in animal diagnostics, IDEXX continues to drive advancements in veterinary medicine and enhance animal healthcare globally.

Who are the main competitors of IDEXX Laboratories in the market?

The main competitors of IDEXX Laboratories Inc in the market are Zoetis Inc, Heska Corporation, and Abaxis, Inc.

In which industries is IDEXX Laboratories primarily active?

IDEXX Laboratories Inc is primarily active in the animal health industry.

What is the business model of IDEXX Laboratories?

IDEXX Laboratories Inc is a global leader in veterinary diagnostics and software solutions. Their business model revolves around providing innovative products and services to veterinary practices, livestock producers, and pharmaceutical companies. IDEXX offers a wide range of diagnostic tests, instruments, and consumables that aid in the detection and prevention of diseases in animals. Their software solutions enable veterinary practices to streamline their operations, manage patient data, and enhance overall patient care. With a strong focus on research and development, IDEXX continuously strives to introduce advanced technologies and improve the quality of veterinary care worldwide.

What is the P/E ratio of IDEXX Laboratories 2025?

The IDEXX Laboratories P/E ratio is 37.65.

What is the P/S ratio of IDEXX Laboratories 2025?

The IDEXX Laboratories P/S ratio is 8.97.

What is the Quality Investing of IDEXX Laboratories?

The Quality Investing for IDEXX Laboratories is 10/10.

What is the revenue of IDEXX Laboratories 2025?

The expected IDEXX Laboratories revenue is 4.2 B USD.

How high is the profit of IDEXX Laboratories 2025?

The expected IDEXX Laboratories profit is 1 B USD.

What is the business model of IDEXX Laboratories

IDEXX Laboratories Inc is a leading company in the field of animal health diagnostics and biotechnology. The company's business model is to offer innovative solutions to veterinarians, pet owners, and animal caretakers to improve the health and well-being of animals. IDEXX is divided into three main divisions: diagnostics and software, water testing, and animal genetics. Each division offers specialized products and services to meet the individual needs and requirements of customers. The diagnostics and software division of IDEXX offers a wide range of tests and instruments for the diagnosis of diseases in animals. The products range from simple blood tests to complex pathological examinations. IDEXX Labs specializes in tests for dogs, cats, and horses, offering a wide range of diagnostic options for these animals. The company also works closely with veterinarians and veterinary clinics to provide a wide range of diagnostic and laboratory services. In the water testing division, the company develops solutions for the detection of contaminants in drinking water and bottled water. This area of the business is focused on companies and government agencies that monitor the condition of water and want to ensure that it is safe for consumption. The animal genetics division of IDEXX offers breeding programs and tests for animals. The foundation of this division's work is DNA sequencing, which allows for the identification of genetic factors that can impact the health and behavior of animals. The animal genetics department works with veterinarians and pet owners to provide customer-oriented services that contribute to the improvement of animal health and breed. IDEXX is committed to providing its customers with innovative and advanced solutions. The company continuously invests in research and development to bring new products to the market and improve its existing offerings. IDEXX's business model is based on creating value by helping veterinarians and animal caretakers improve the health, well-being, and quality of life of animals. IDEXX also aims to integrate its products and services into the online market. To achieve this, the company develops various software solutions to ensure better portability and convenient connections to its services for customers. IDEXX is already involved in telemedicine, offering pet owners the opportunity to speak with veterinarians online and receive diagnoses. Overall, IDEXX's business model is focused on providing a comprehensive platform for animal health and biotechnology. Through its divisions in diagnostics, water testing, and animal genetics, the company has developed a wide range of products and solutions aimed at improving the health and well-being of animals and providing customers with high value.

What is the IDEXX Laboratories dividend?

IDEXX Laboratories pays a dividend of 0 USD distributed over payouts per year.

How often does IDEXX Laboratories pay dividends?

The dividend cannot currently be calculated for IDEXX Laboratories or the company does not pay out a dividend.

What is the IDEXX Laboratories ISIN?

The ISIN of IDEXX Laboratories is US45168D1046.

What is the IDEXX Laboratories WKN?

The WKN of IDEXX Laboratories is 888210.

What is the IDEXX Laboratories ticker?

The ticker of IDEXX Laboratories is IDXX.

How much dividend does IDEXX Laboratories pay?

Over the past 12 months, IDEXX Laboratories paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, IDEXX Laboratories is expected to pay a dividend of 0 USD.

What is the dividend yield of IDEXX Laboratories?

The current dividend yield of IDEXX Laboratories is .

When does IDEXX Laboratories pay dividends?

IDEXX Laboratories pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of IDEXX Laboratories?

IDEXX Laboratories paid dividends every year for the past 0 years.

What is the dividend of IDEXX Laboratories?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is IDEXX Laboratories located?

IDEXX Laboratories is assigned to the 'Health' sector.

Wann musste ich die Aktien von IDEXX Laboratories kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of IDEXX Laboratories from 2/23/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 2/23/2025.

When did IDEXX Laboratories pay the last dividend?

The last dividend was paid out on 2/23/2025.

What was the dividend of IDEXX Laboratories in the year 2024?

In the year 2024, IDEXX Laboratories distributed 0 USD as dividends.

In which currency does IDEXX Laboratories pay out the dividend?

The dividends of IDEXX Laboratories are distributed in USD.

All fundamentals about IDEXX Laboratories

Our stock analysis for IDEXX Laboratories Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of IDEXX Laboratories Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.